Societe Generale downgraded Merck to Hold from Buy.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRK:
- Merck reports NRG-GY018 trial shows statistical significance, improvement in PFS
- Merck provides update from open-label arm of Phase 2 KeyVibe-002 trial
- Merck downgraded at Wells Fargo on valuation, lack of catalysts
- Merck downgraded to Equal Weight from Overweight at Wells Fargo
- Merck says Phase 2/3 CCTG IND.227/KEYNOTE-483 trial met primary endpoint